Hépato-Gastro & Oncologie Digestive
MENUSkin adverse events of anti-tumor necrosing factor agents in IBD Volume 25, issue 6, Juin 2018
- Key words: Inflammatory Bowel Disease, Crohn's disease, ulcerative colitis, anti-TNFα agents, skin infections, paradoxical psoriasis
- DOI : 10.1684/hpg.2018.1631
- Page(s) : 598-606
- Published in: 2018
Cutaneous adverse events are frequent among patients with inflammatory bowel disease (IBD) treated by anti-Tumor Necrosis Factor (TNF)- α agents, concerning 20% of patients. Infections represent half of skin complications, immune-mediated lesions 40% and, neoplastic lesions and local reactions the remaining percentage. Infections that are mostly caused by bacteria or herpes virus reactivation can usually be treated without anti-TNFα withdrawal. Psoriasis and eczema lesions have typical locations, with a palmo-plantar involvement, folds and scalp eruptions. They could be treated in most of cases with topical steroids and vitamin D. Few patients have to stop anti-TNFα and switch to drug with another mode of action. Dermatologic surveillance is now yearly recommended in IBD patients.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License